Introduction {#S1}
============

Bone fracture healing is a tightly regulated process involving different cell types. The first hours after trauma are characterized by hematoma formation and an acute inflammatory response. Blood and bone marrow-derived leukocytes express pro-inflammatory cytokines and initiate the healing process. Eventually, mesenchymal stem cells (MSC) are attracted from the surrounding tissue, bone marrow, and/or the circulation (Shirley et al., [@B112]) to serve as osteoprogenitor cells. Different mechanisms have been described for the homing of MSCs to the fracture site.

Mesenchymal stem cells express the chemokine receptor CXCR4, and MSC migration toward stromal cell-derived factor-1 (SDF-1) has been confirmed *in vitro* and *in vivo* (Abbott et al., [@B1]; Ji et al., [@B45]; Wynn et al., [@B122]). At injury sites, tissue ischemia induces expression of hypoxia-inducible factor-1 (HIF-1), which in turn triggers SDF-1 expression (Ceradini et al., [@B9]). Accordingly, upregulation of SDF-1 expression was shown during fracture healing in mice (Kitaori et al., [@B58]). Further, it has been shown that osteoblast progenitor cells express CXRC4 prompting their migration to regions of new bone formation (Otsuru et al., [@B96]). Inhibition of SDF-1 or blocking of its receptor, CXCR4, prevents MSC recruitment and results in impaired bone healing (Kitaori et al., [@B58]). It has also been shown that long-term administration of the CXCR4 antagonist AMD3000 specifically decreases hyaline cartilage volume at early time points, as well as the volume of callus and mineralized bone at later stages of the healing cascade (Toupadakis et al., [@B117]).

Along with other pro-inflammatory cytokines, tumor necrosis factor alpha (TNFα) accumulation peaks in the first 24 h after fracture and again during the remodeling phase (Kon et al., [@B61]). Transgenic mice lacking the TNFα receptor suffer from impaired intra-membranous bone formation suggesting a critical role of TNFα in fracture healing (Gerstenfeld et al., [@B32]). It has been further suggested that TNFα is specifically involved in the attraction of osteoprogenitor cells from surrounding soft tissues (Glass et al., [@B33]). However, depending on the concentration, TNFα may also have an anti-regenerative effect. In a murine model of subcutaneous bone formation, it has been demonstrated that T-lymphocyte secreted TNFα-induced apoptosis of transplanted MSCs, which resulted in inhibition of new bone formation (Liu et al., [@B76]).

Revascularization is a critical step in the process of fracture healing (Laroche, [@B68]). Vascularization ensures an adequate nutrient supply, the removal of metabolic waste products, and supports the influx of immune and progenitor cells from the circulation. Revascularization is mediated by two different mechanisms: (i) angiogenesis: involving sprouting and ingrowth from pre-existing blood vessels, i.e., from the periosteum and (ii) the *de novo* formation of blood vessels by endothelial progenitor cells (EPCs) referred to as neovascularization. The importance of neovascularization in bone healing is evident from the fact that mobilization of EPCs has been observed after musculoskeletal trauma (Laing et al., [@B67]), fracture (Matsumoto et al., [@B86]), and during fracture healing (Ma et al., [@B79]).

Endothelial progenitor cell mobilization and homing mechanisms have been studied in great detail in the context of ischemic diseases; for review, see Verloop et al. ([@B118]); vascular endothelial growth factor (VEGF) and SDF-1 have been identified as key mediators of EPC mobilization (Asahara et al., [@B2]; Kawakami et al., [@B52]). Besides SDF-1, VEGF is also expressed in bone, and VEGF serum levels have been shown to increase after polytrauma (Grad et al., [@B34]). Thus, both factors contribute to the recruitment of EPCs to the fracture site. Furthermore, VEGF is expressed by hypertrophic chondrocytes and plays a crucial role in endochondral ossification (Gerber et al., [@B31]). Interestingly, it has been proposed that VEGF does not only stimulate angiogenesis during fracture repair but also has a direct effect on osteoblast attraction and differentiation as well as bone turnover (Mayr-Wohlfart et al., [@B88]; Street et al., [@B115]; Orlandini et al., [@B95]).

Stem cell recruitment is a critical step in bone regeneration, and failed healing has been correlated with a decreased MSC pool in patients suffering from atrophic non-union fractures (Mathieu et al., [@B84]). Similarly, a lack in vascularization leads to delayed or failed tissue regeneration. In this review, we first summarize tissue engineering strategies focusing on the local delivery of homing factors. We then present an overview of the approaches to mobilize stem cells from their niche in order to increase the pool of circulating stem cells. Finally, the clinical challenges of critical-size bone defects and fracture non-union repair are discussed in context to the development of future cell-based therapies.

Strategies to Promote Homing {#S2}
============================

Different approaches have been used to deliver homing factors to the fracture site (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}B).

###### 

**Homing factors for bone regeneration**.

  Agent                                             Delivery system                               Animal model                    Reference
  ------------------------------------------------- --------------------------------------------- ------------------------------- --------------------------------------------------
  **Protein delivery**                                                                                                            
  FGF-2                                             Collagen sponge                               Mouse, calvarial defect         Behr et al. ([@B4])
                                                                                                                                  
  PDGF-BB                                           Fibrin gel                                    Rat, femur delayed union        Kaipel et al. ([@B50])
                                                                                                                                  
  PDGF-BB + BMP-2                                   Fibrin gel (functionalized)                   Rat, calvarial defect           Martino et al. ([@B83])
                                                                                                                                  
  PDGF-BB/PlGF-2~123-144~ + BMP-2 PlGF-2~123-144~   Saline or fibrin gel                          Rat, calvarial defect           Martino et al. ([@B82])
                                                                                                                                  
  SDF-1                                             Collagen gel matrix                           Mouse, DO model                 Fujio et al. ([@B26])
                                                    Fibrin gel                                    Mouse, tibial defect            Li et al. ([@B74])
                                                    PCL/gelatin electrospun membranes             Rat, calvarial defect           Ji et al. ([@B46])
                                                    Collagen sponge                               Mouse, calvarial defect         Jin and Giannobile ([@B48])
                                                    PLGA scaffold                                 Mouse, calvarial defect         Liu et al. ([@B77])
                                                                                                                                  
  SDF-1 + BMP-2                                     Collagen sponge                               Mouse, calvarial defect         Jin and Giannobile ([@B48])
                                                                                                                                  
  SDF-1 + PDGF                                      Collagen sponge                               Mouse, calvarial defect         Jin and Giannobile ([@B48])
                                                                                                                                  
  SDF-1 + VEGF                                      Collagen sponge                               Mouse, calvarial defect         Jin and Giannobile ([@B48])
                                                                                                                                  
  Simvastatin                                       α-TCP                                         Rat, calvarial defect           Nyan et al. ([@B94])
                                                    PLA scaffold                                  Rat, rabbit, calvarial defect   Yueyi et al. ([@B126])
                                                    PLGA scaffold                                 Mouse, calvarial defect         Liu et al. ([@B77])
                                                                                                                                  
  TNF                                               Saline                                        Mouse, tibial defect            Glass et al. ([@B33])
                                                                                                                                  
  VEGF                                              β-TCP                                         Mouse, calvarial defect         Wernike et al. ([@B121])
                                                                                                  Rabbit, ulna defect             Clarke et al. ([@B12])
                                                    CaP coated titanium                           Pig, calvarial defect           Ramazanoglu et al. ([@B104])
                                                    Chitosan sponge                               Rabbit, intercondylar defect    De la Riva et al. ([@B15])
                                                    Collagen                                      Rabbit, mandibular defect       Kleinheinz et al. ([@B59])
                                                    Collagen sponge                               Mouse, calvarial defect         Behr et al. ([@B4]), Jin and Giannobile ([@B48])
                                                    Fibrin                                        Rat, femur delayed union        Kaipel et al. ([@B50])
                                                    Gelatin spheres, PPF scaffold                 Rat, calvarial defect           Patel et al. ([@B98])
                                                                                                  Rat, femoral defect             Kempen et al. ([@B54])
                                                    Hyaluronic acid                               Rabbit, tibial defect           Eckardt et al. ([@B17])
                                                    PLGA scaffold                                 Rat, calvarial defect           Murphy et al. ([@B92]), Kaigler et al. ([@B49])
                                                    PLGA scaffold BG coated                       Rat, calvarial defect           Leach et al. ([@B69])
                                                    PLGA spheres, fibrin                          Dog, femoral neck defect        Zhang et al. ([@B127])
                                                    Silk fibroin/CaP/PLGA                         Rabbit, calvarial defect        Farokhi et al. ([@B22])
                                                                                                                                  
  VEGF + BMP-2                                      Allograft, PLGA                               Rat, femoral defect             Mattar et al. ([@B87])
                                                    CaP coated titanium                           Pig, calvarial defect           Ramazanoglu et al. ([@B104])
                                                    Gelatin spheres in PPF scaffold               Rat, calvarial defect           Patel et al. ([@B98])
                                                                                                  Rat, femoral defect             Kempen et al. ([@B54])
                                                    PLGA, alginate                                Mouse, femoral defect           Kanczler et al. ([@B51])
                                                    Silk fibroin                                  Rabbit, maxillary sinus         Zhang et al. ([@B130])
                                                                                                  Rabbit, calvarial defect        Zhang et al. ([@B128])
                                                                                                  Rat, calvarial defect           Zhang et al. ([@B129])
                                                                                                                                  
  VEGF + PDGF-BB                                    Silk fibroin/CaP/PLGA                         Rabbit, calvarial defect        Farokhi et al. ([@B21])
                                                                                                                                  
  **Plasmid/virus delivery**                                                                                                      
  VEGF                                              AV, intramuscular injection                   Rat, femur drill hole           Tarkka et al. ([@B116])
                                                    plasmid-DNA                                   Rabbit, radius defect           Geiger et al. ([@B29])
                                                    Corraline scaffold coated with plasmid-DNA    Rabbit, radius defect           Geiger et al. ([@B30])
                                                                                                                                  
  **Genetically manipulated cells**                                                                                               
  MCP-3                                             LV-transduced MSC, bone graft                 Mouse, fibular osteotomy        Shinohara et al. ([@B111])
  SDF-1                                             AV-transduced MSC, collagen sponge            Rat, femoral defect             Ho et al. ([@B40])
                                                    LV-transduced MSC, bone graft                 Mouse, fibular osteotomy        Shinohara et al. ([@B111])
                                                                                                                                  
  SDF-1 + BMP-2                                     AV-transduced fat tissue graft                Mouse, femoral defect           Zwingenberger et al. ([@B132])
                                                                                                                                  
  VEGF                                              Plasmid-transfected MSC, corraline scaffold   Rabbit, radius defect           Geiger et al. ([@B30])
                                                                                                  Rabbit, orbital defect          Xiao et al. ([@B123])
                                                    Plasmid-transfected fibroblasts, gelfoam      Rabbit, tibial defect           Li et al. ([@B73])
                                                                                                                                  
  VEGF + BMP-2                                      AV-transduced MSC, corraline scaffold         Rabbit, orbital defect          Xiao et al. ([@B123])
                                                    BV-transduced ASC, PLGA scaffold              Rabbit femoral defect           Lin et al. ([@B75])
                                                                                                                                  
  VEGF + BMP-4                                      RV-transduced MDSC, gelfoam                   Mouse, skull defect             Peng et al. ([@B102])

*The table lists chemoattractants, which have been delivered as protein or on the gene level to the bone defect site. Alternatively, genetic manipulation has been applied to overexpress homing factors in transplanted cells. Of note, the table includes only factors, which have been tested in orthotopic models of bone regeneration in vivo. ASC, adipose-derived stem cells; AV, adenovirus; BV, hybrid baculovirus; DO, distraction osteogenesis; LV, lentivirus; MDSC, muscle-derived stem cells; PCL, poly(epsilon-caprolactone); PPF, poly(propylene fumarate); RV, retrovirus*.

![**Cell therapy vs. homing and mobilization of native cells for bone regeneration**. **(A)** For an autologous cell transplantation, donor cells have to be harvested and expanded *in vitro* before they are eventually re-transplanted in the patient. The amplified cells can be seeded on a biomaterial or incorporated in a carrier for local administration or injected in the circulation to increase the pool of available stem cells, which in turn may home to the defect site. **(B)** Homing factors are directly delivered to the defect site. The release and diffusion of the factor create a gradient subsequently attracting stem and progenitor cells from the local tissue environment or the circulation. **(C)** Native stem and progenitor cells may be mobilized into the circulation by the administration of a stimulation factor enhancing the level of available cells.](fbioe-03-00079-g001){#F1}

In scaffold-based tissue engineering strategies, homing factors can be covalently bound or absorbed to the scaffold. Drug delivery systems such as hydrogels, microspheres, and nanoparticles have been used on their own or in combination with scaffolds and/or biomaterials (see Local delivery of Homing Factors). Of note, the carrier material has a significant impact on the release profile of the homing factor in question. Alternatively, protein may be delivered via plasmid- or virus-based induction of homing factors (see Delivery of Genes). A recent study incorporated angiogenic and osteogenic small interfering RNAs into a tissue-engineered construct for bone regeneration (Jia et al., [@B47]). Finally, co-transplanted cells have been targeted to promote expression of homing factors by genetic manipulation (see Genetically Manipulated Cells). In the case of MSCs, the natural secretome itself might be a source of chemoattractants (Caplan et al., [@B8]; Kinnaird et al., [@B57]; Stoddart et al., [@B114]), which in turn mediate recruitment of endothelial cells (Seebach et al., [@B110]).

Local delivery of homing factors {#S2-1}
--------------------------------

For the local administration of growth factors, different delivery strategies have been investigated as reviewed by Chen et al. ([@B10]). The delivery system determines the release profile of the growth factor and has to be carefully chosen based on the requirements of the targeted tissue. Most systems display a continuous release of the growth factor. Here, the direct adsorption of growth factors results in a burst release, while a sustained and delayed release can be achieved by encapsulation of growth factors in microspheres (Chen et al., [@B10]). A responsive system can be created, whereby growth factors are entrapped, ionically or covalently bonded to the carrier material. Growth factor release is then indirectly modulated by physical and chemical microenvironmental changes.

Vascular endothelial growth factor is a key mediator in angiogenesis, but has also been suggested to directly support bone formation. This dual function has made VEGF an attractive target for bone tissue engineering in the past decade. Recombinant VEGF has been delivered with various biomaterials and tested in different preclinical bone fracture models. VEGF delivery with poly(lactide-co-glycolide) (PLGA) scaffolds has been shown to increase vascular density as well as bone mineral formation in a critical-size cranium defect (Murphy et al., [@B92]) and calvarial defects (Kaigler et al., [@B49]) in rats. A similar positive outcome was reported when VEGF was administered on a (i) collagen sponge into mandibular (Kleinheinz et al., [@B59]) or calvarial defects (Behr et al., [@B4]; Jin and Giannobile, [@B48]); (ii) polymeric scaffolds with a bioactive glass coating (Leach et al., [@B69]) in a rat critical-size defect; and (iii) β-tricalcium phosphate scaffold in a rabbit ulna defect (Clarke et al., [@B12]). By contrast, other studies failed to show a beneficial effect of VEGF delivery on bone regeneration in different models including a rabbit non-union model (Geiger et al., [@B29]), a rat model of delayed union (Kaipel et al., [@B50]), and an ectopic bone formation model using cancellous bone scaffolds (Lenze et al., [@B70]).

It has been shown that adsorbed VEGF is released within few days (Leach et al., [@B69]; Kempen et al., [@B54]). A too high local concentration of VEGF might, however, cause malformation and malfunction of blood vessels (Neufeld et al., [@B93]; Ozawa et al., [@B97]). In addition, a more sustained release of VEGF might be desirable to efficiently support vascularization and bone formation. Therefore, several studies attempted a more controlled release of VEGF aiming to sustain a low dose of VEGF during the first weeks after trauma. Mostly, these approaches follow the route of encapsulation of VEGF in microspheres or nanoparticles. Pre-encapsulation of VEGF in PLGA microspheres before scaffold fabrication has been shown to delay the growth factor release compared to direct incorporation into PLGA scaffolds (Ennett et al., [@B19]). Encapsulation of VEGF in alginate microspheres delivered with a chitosan/poly(lactide) scaffold has also been promising, showing only a 13% release within the first 24 h followed by a sustained release throughout 5 weeks (De la Riva et al., [@B14], [@B15]). Similarly, encapsulation of VEGF in gelatin microparticles, which have been included in a composite scaffold, could maintain VEGF bioactivity above 90% over 14 days (Patel et al., [@B98]). In orthotopic bone formation models, VEGF delivery via a PLGA-composite scaffold has shown a sustained VEGF release over 28 days, resulting in new bone formation observed 10 weeks after implantation in a rabbit cranial defect (Farokhi et al., [@B21], [@B22]). Similarly, the combined administration of PLGA-encapsulated VEGF with fibrin resulted in a sustained VEGF release for up to 42 days, with improved vascularization and accelerated healing of a femoral head fracture model in dogs (Zhang et al., [@B127]). Burst release of VEGF was also prevented by co-precipitating VEGF onto basic calcium phosphate (BCP), resulting in vascularization and osseointegration of the biomaterial, and finally to new bone formation in a critical-size cranial defect in Balb/c mice (Wernike et al., [@B121]).

Ehrbar and colleagues introduced an innovative approach to control the release of VEGF by cell-mediated enzyme activity (Ehrbar et al., [@B18]). Here, authors engineered a recombinant form of VEGF containing an alpha~2~-plasmin inhibitor (alpha~2~-PI~1-8~) sequence, which is a substrate for factor XIIIa. Covalently linked to the fibrin matrix, alpha~2~-PI~1-8-~VEGF is released upon remodeling of the fibrin by cell-associated enzymatic activity, such as plasmin or matrix metalloproteinases. Authors demonstrated that cell-controlled release of the VEGF from the fibrin gel carrier led to an increase in formation of new arterial and venous branches in an embryonic chicken chorioallantoic membrane model (Ehrbar et al., [@B18]). Recently, it was shown that the system was therapeutically effective both in ischemic hind limb and wound-healing models (Sacchi et al., [@B107]).

Several studies have combined VEGF with other chemoattractive or osteoinductive factors. For example, VEGF has been applied in combination with BMP-2. Most of these studies showed the expected strong osteoinductive effect of BMP-2. However, further addition of VEGF, while leading to slightly increased vascular density, did not exhibit enhanced bone formation (Patel et al., [@B99]; Kempen et al., [@B54]; Young et al., [@B125]; Kanczler et al., [@B51]; Zhang et al., [@B130], [@B128]; Mattar et al., [@B87]; Ramazanoglu et al., [@B104]; Cai et al., [@B7]). Interestingly, Kempen and colleagues presented a delivery system allowing for a sequential release of the two growth factors. Here, BMP-2 was encapsulated in PLGA microspheres, which were delivered in a poly(propylene) scaffold surrounded by a gelatin hydrogel loaded with VEGF (Kempen et al., [@B54]).

Platelet-derived growth factor (PDGF) is involved in angiogenesis, in particular, it mediates migration of pericytes from the vessel wall toward sites of new vessel formation, which is thought to be critical for the stabilization of newly formed blood vessels (Armulik et al., [@B133]). In addition, a chemoattractive effect of PDGF-BB on MSCs has been reported (Fiedler et al., [@B24]). This was confirmed in a study testing the release of PDGF-BB from a poly(ϵ-caprolactone) (PCL) -- collagen -- hydroxyapatite scaffolds, showing a sustained release of bioactive PDGF-BB, which was able to stimulate MSC migration (Phipps et al., [@B103]). Interestingly, PDGF-BB has been FDA approved for periodontal repair (Pellegrini et al., [@B101]). Recently, PDGF delivery has been tested in orthotopic bone formation models. Here, administration of PDGF on a collagen sponge in a critical-size calvarial defect has been shown to increase bone mineral content to a similar extent than VEGF, but significantly less than BMP-2 (Jin and Giannobile, [@B48]). In line with this, in a rat model of delayed union, PDGF-BB delivery alone did not support bone formation (Kaipel et al., [@B50]). Farokhi et al. ([@B21]) studied the controlled release of VEGF and PDGF from a silk/calcium phosphate/PLGA scaffolds and found that the combination of the two homing factors supported new bone formation and neovascularization in a rabbit drill hole model. Martino and co-workers reported that the delivery of PDGF-BB and BMP-2 in a fibrin gel functionalized with an integrin binding domain and allowing for sequestration of the growth factors greatly enhanced bone regeneration in a rat calvarial defect compared to growth factors encapsulated in unmodified fibrin (Martino et al., [@B83]). Recently, the same group reported on an interesting approach to fuse extracellular matrix super-affinity binding sites to growth factors. Applying such engineered variants of PDGF-BB and BMP-2 for the treatment of a calvarial defect in rats resulted in greater bone regeneration compared to wild type growth factors (Martino et al., [@B82]).

The recruitment of MSCs to the fracture site is predominantly regulated via the SDF-1 -- CXCR4 axis (Kitaori et al., [@B58]). Interestingly, homing of EPCs may be triggered by the same pathway. Accordingly, several tissue engineering strategies have been using SDF-1 to stimulate MSC and EPC homing. Indeed, local administration of SDF-1 in a distraction osteogenesis mouse model has been shown to increase the recruitment of MSCs and EPCs, to induce callus formation and blood flow (Fujio et al., [@B26]). Li and colleagues reported that SDF-1 administered in fibrin glue enhanced the healing process in a mouse tibia fracture model with intramedullary fixation (Li et al., [@B74]).

Absorption of SDF-1 to an electrospun gelatin/PCL membrane was shown to efficiently recruit MSCs to a cranial defect and resulted in a sixfold increase in bone formation compared to membrane alone (Ji et al., [@B46]). A positive effect on MSC recruitment and bone formation was also shown for PLGA loaded with SDF-1 in a critical-size calvarial defect in mice (Liu et al., [@B77]). A comparative study evaluating the effect of different chemoattractants applied on a collagen sponge in a critical-size calvarial defect is presented by Jin and Giannobile ([@B48]). The authors report on a moderate effect on bone formation by SDF-1 alone or in combination with PDGF or VEGF. By contrast, significant more bone volume was seen when SDF-1 was administered in combination with BMP-2. In a model of ectopic bone formation, Chim et al. ([@B11]) used a customized microdelivery apparatus to maintain constant cytokine release over a period of 4 weeks within the subcutaneous implanted PLGA scaffolds. The experiment revealed that a higher cellular infiltration was seen when SDF-1 was administered in addition to BMP-2 or TGFβ.

It has been reported that statins, such as simvastatin, have the potential to induce bone formation (Mundy et al., [@B91]). Recent work suggested that this effect is driven by the stimulation of MSC and EPC homing. Accordingly, simvastatin-based tissue engineering strategies showed increased recruitment of osteoprogenitor cells and EPCs (Nyan et al., [@B94]; Yueyi et al., [@B126]). Furthermore, it has been suggested that the outcome of such approaches may be improved by combining simvastatin and SDF-1 (Liu et al., [@B77]). On the other hand, an *in vitro* study suggested that high doses of statins may have a cytotoxic effect on MSCs (Kupcsik et al., [@B64]).

Besides SDF-1, it has been suggested that TNFα plays a role in the recruitment of osteoprogenitor cells to the fracture site and local injection of TNFα upon initiation of trauma and the day after accelerated fracture healing (Glass et al., [@B33]).

An alternative approach to the use of defined amounts of recombinant growth factors are platelet-released growth factors. Platelet-rich plasma (PRP) refers to a concentrate of blood platelets, which upon activation releases various growth factors, including VEGF, CCL5, PDGF-AB, and PDGF-BB (Fekete et al., [@B23]). Although standard protocols for the preparation of PRP are missing and its efficacy is under debate, PRP in combination with scaffolds or bone graft has been variously used in preclinical and clinical approaches. These studies have been reviewed elsewhere and are not described in this article (Malhotra et al., [@B80]).

Another method is to use the secretome of MSCs. Wang et al. ([@B119]) demonstrated that a galantine sponge soaked in MSC-conditioned medium supported angiogenesis and bone healing in a model of fracture non-union in diabetic rats.

Delivery of genes {#S2-2}
-----------------

Gene therapies have been developed aiming to deliver the genetic information of homing factors into the defect site, with VEGF being the main target gene. Gene delivery methods have the main advantage to promote sustained and regulated expression of proteins at the defect site (Evans, [@B20]). Some approaches incorporate plasmids in tissue-engineered constructs; however, low efficacy prompted researchers to develop alternative approaches, such as adenoviral delivery of the genetic information. While dramatically increasing gene transfer efficiency, there are also drawbacks to the use of viral vectors. Lentiviral and retroviral vectors permanently modify the cells genome, with the risk of insertional mutagenesis. Adenoviral transduction has the advantage that the absence of vector genome integration minimizes the risk of germ-line transmission and insertional mutagenesis. It does, however, trigger an immunological response at higher doses. Adeno-associated virus (AAV) is increasing in popularity due to its low immunogenicity and lack of integration. AAV vectors are currently difficult to produce to a high titer.

Geiger et al. ([@B29]) report on a VEGF-gene-activated matrix promoting vascularization and bone formation in a critical-size radius defect in rabbits. A positive effect of VEGF on vascularization was also reported in an ectopic bone formation model in mice, while the most efficient bone formation was detected in constructs containing MSCs along with VEGF and BMP-4 plasmids (Huang et al., [@B42]). It has been shown that local administration of a VEGF adenovirus in the distal femur of rabbits was able to transduce endogenous bone marrow cells and in turn to enhance osteoblast number, osteoid volume, and bone volume (Hiltunen et al., [@B38]). In a rat femoral defect, injection of a VEGF adenovirus in the adjacent muscle has shown to promote endochondral bone healing (Tarkka et al., [@B116]). Similarly, it has been shown that a VEGF adenoviral vector containing chitosan/hydroxyapatite scaffold promoted recruitment of endogenous endothelial cells and supported ectopic bone formation (Koc et al., [@B60]).

Genetically manipulated cells {#S2-3}
-----------------------------

Transplantation of autologous stem cells is widely used in bone tissue engineering strategies. Several studies have used genetically modified cells to induce expression of homing factors, which in turn promotes the recruitment of host osteogenic and EPCs. Here, most studies have applied viral transduction strategies (for details, see Table [1](#T1){ref-type="table"}) to introduce the specific gene sequence prior to transplantation of cells into the bone defect. Again, the main interest has been in overexpression of VEGF.

Promising results were reported for adipose-derived stem cells (ASCs) transduced with an adenovirus to release VEGF that led to vascular ingrowth into PLGA scaffolds (Jabbarzadeh et al., [@B44]). An approach using VEGF-plasmid-transfected fibroblasts showed improved vascularization and bridging of a segmental bone defect in rabbits, while unmodified fibroblasts did not support bone regeneration (Li et al., [@B73]). By contrast, a study comparing the healing of a critical-size radius defect in rabbits revealed that substantial bone formation was only seen in groups with MSCs transfected with control plasmid, while VEGF transfected MSCs prompted a higher vascular density (Geiger et al., [@B30]). In line with this, Helmrich and colleagues demonstrated that subcutaneously implanted osteogenic constructs containing MSCs, transduced with a retroviral vector to overexpress VEGF, led to an increase in vascular density but caused a global decrease in bone quality by increasing the recruitment of osteoclasts (Helmrich et al., [@B36]).

In order to also address osteoinduction, several groups followed a combined approach with overexpression of VEGF and BMP-2. Cell transplantation of human periosteum-derived cells transfected with VEGF and BMP-2 plasmids resulted in improved osteogenesis and vascularization in an ectopic bone formation model and a critical-size orbital defect (Samee et al., [@B108]). A similar finding was reported with adenoviral-transduced MSCs (Xiao et al., [@B123]). Long time evaluation of the healing of a rabbit femoral defect treated with baculovirus-engineered ASCs overexpressing VEGF/BMP-2 further revealed a positive effect on endochondral ossification and bone remodeling (Lin et al., [@B75]). A similar observation was made in a study applying retroviral-transduced muscle-derived stem cells overexpressing BMP-4 and VEGF in a skull defect in mice (Peng et al., [@B102]). Adenoviral delivery of the angiogenic factor angiopoitin-1 (ANG-1) along with BMP-2 and VEGF led to enhanced osteogenesis and angiogenesis in a rabbit radial defect treated with MSCs overexpressing all three factors compared to the other study groups (Hou et al., [@B41]).

A study from Shinohara et al. ([@B111]) suggested that lentiviral-overexpression of SDF-1 or monocyte chemotactic protein-3 (MCP-3) may be used to attract MSCs to the fracture site. The authors performed a parabiosis of a GFP and a wild-type mouse and studied the homing of GFP-positive stem cells into an osteotomy gap in the wildtype mouse; this experiment revealed significantly enhanced cell recruitment when the defect was treated with MSCs overexpressing MCP-3 or SDF-1 (Shinohara et al., [@B111]). The stimulatory effect of SDF-1 on cell homing was confirmed in a study applying SDF-1- and/or BMP-2-lentivirus-transduced fat grafts in a femoral defect in mice (Zwingenberger et al., [@B132]), a significant increase in bone volume compared to untreated fat grafts was, however, only observed in groups with combined expression of both factors. A rat study testing the effect of SDF-1-adenovirus-transduced MSCs implanted on a collagen sponge in a femoral defect showed a significant increase in new bone formation compared to cell-free or untransduced control groups (Ho et al., [@B40]).

Stem Cell Stimulation {#S3}
=====================

Local or systemic transplantation of stem- and progenitor cells has been used for bone tissue engineering and bone regeneration (Figure [1](#F1){ref-type="fig"}A). For example, transplantation of EPCs has shown promising results with regards to the regeneration of vascularized bone tissue (Matsumoto et al., [@B85]; Kuroda et al., [@B65], [@B66]). These strategies have several limitations. Harvesting of cells is associated with donor site morbidity, pain, and additional hospitalization of the patient. Cell purification and expansion is expensive and time consuming and associated with safety concerns such as mutagenesis or contaminations. Therefore, there has been an interest to circumvent cell harvesting and amplification steps and to develop strategies to stimulate the mobilization of native endogenous stem cells (Figure [1](#F1){ref-type="fig"}C).

Granulocyte colony-stimulating factor (G-CSF) induces the mobilization of CD34-positive, hematopoietic cells representing a source of EPCs (Peichev et al., [@B100]). Subsequently, G-CSF has been used to enrich CD34-positive cells prior cell harvest and local or systemic transplantation (Mifune et al., [@B90]; Kuroda et al., [@B65]). In addition, G-CSF has been applied as a homing factor at the defect site in a segmental bone defect (Ishida et al., [@B43]). Finally, some studies evaluated the effect of G-CSF stimulation in bone defect models hypothesizing that the enhanced accumulation of CD34-positive progenitor cells may promote revascularization and thus bone healing (Bozlar et al., [@B5]; Kaygusuz et al., [@B53]; Marmotti et al., [@B81]). Indeed subcutaneous injection of G-CSF on seven consecutive days after creation of a tibia defect in rats accelerated bone healing (Bozlar et al., [@B5]); in line with this another study reported improved fracture healing scores in a tibia defect model in rats after administration of G-CSF (Kaygusuz et al., [@B53]). A recent phase II clinical trial evaluated the preoperative administration (three consecutive days) of G-CSF in patients undergoing opening-wedge high tibial valgus osteotomy (Marmotti et al., [@B81]). The study including 12 patients in both the G-CSF treated- and the control group, reported on a successful mobilization of CD34-positive cells upon surgery, which in turn resulted in an improved osseointegration of grafts (Marmotti et al., [@B81]).

The SDF-1/CXCR4 axis is involved in the retention of hematopoietic progenitor cells in the bone marrow (Levesque et al., [@B72]). Accordingly, it has been shown that AMD3100, a CXCR4 antagonist promotes stem cell mobilization into the circulation, with the most efficient cell mobilization seen in combination with G-CSF (Broxmeyer et al., [@B6]). Conversely, the biological function of AMD3100-mobilized cells has been questioned in an *in vitro* study (Yin et al., [@B124]). In addition, interference with the SDF-1/CXCR4 axis can also impair homing of stem cells toward the defect site (Toupadakis et al., [@B117]). Nonetheless, a positive effect of AMD3100 administration on the healing of a segmental defect in mice was reported (Kumar and Ponnazhagan, [@B63]). The authors show that a combined treatment with insulin-like growth factor-1 (IGF-1) and AMD3100 resulted expectably in an increased accumulation of colony-forming cells and finally augmented bone growth (Kumar and Ponnazhagan, [@B63]).

It has been suggested that low-intensity pulsed ultrasound (LIPUS) might be used to promote fracture healing (Duarte, [@B16]; Leung et al., [@B71]; Khan and Laurencin, [@B56]). Interestingly, a recent study investigating the underlying mechanisms revealed that LIPUS stimulates MSC homing to the fracture site by upregulating local and serum SDF-1 levels (Wei et al., [@B120]).

Sildenafil, a potent vasodilator and stimulator of angiogenesis, has been proposed to increase circulating EPCs (Foresta et al., [@B25]) and sildenafil has been used for the treatment of ischemic diseases (Hart et al., [@B35]; Koneru et al., [@B62]). Histing et al. ([@B39]) investigated the effect of sildenafil during the process of fracture healing in a drill hole model in mice. The study revealed that daily oral administration of sildenafil accelerated bone healing indicated by increased osseous fracture bridging, biomechanical stiffness, and a smaller callus area after 2 weeks (Histing et al., [@B39]).

Challenges and Future Perspectives {#S4}
==================================

Bone has a high natural regeneration capacity. Tissue engineering strategies and cell therapies for bone repair are focusing on critical-size defects and fracture non-unions, which fail to heal spontaneously. A main challenge is the treatment of atrophic non-unions, which are defined as bone defects showing no healing progress within 6 months after fracture. This has been associated with risk factors including smoking and chronic diseases like diabetes (Gaston and Simpson, [@B28]) but may also be idiopathic. In both cases, the underlying mechanisms still remain elusive. A better understanding of the pathology of non-unions will certainly help to find new treatment strategies. A major limitation preventing the development of efficient therapies so far is the lack of appropriate animal models. While various non-union models in rodents, rabbits, and sheep have been established (Garcia et al., [@B27]), most of these models only simulate the situation of a non-healing critical-size defect in a healthy environment and those parameters resulting in non-unions in humans are not addressed. Accordingly, therapies proven successful in preclinical models might thus be ineffective upon clinical application.

The availability of stem and progenitor cells might be a crucial factor for bone healing. A low number of bone marrow progenitor cells were found in patients suffering from pseudoarthrosis (Hernigou and Beaujean, [@B37]). Similarly, it has been reported that the number of circulating progenitor cells was significantly lower in patients with non-union fractures compared to healthy individuals (Seebach et al., [@B109]). Interestingly, the authors further report on an elevated stem cell accumulation in polytrauma patients; at the same time polytrauma is also associated with increased serum accumulation of VEGF (Grad et al., [@B34]). Recent work evaluated the abundance of EPCs in patients with atrophic non-unions (Mathieu et al., [@B84]). In line with the previous studies, a decreased pool of MSCs was detected; but the EPC level was not affected. Future studies will be required to verify these results and to assess stem and progenitor cell availability, mobilization, and recruitment in non-union fractures in detail. However, assuming that fracture non-unions are indeed correlated with a decreased pool of circulating and bone marrow MSCs, this would be a major limitation for cell-based therapies in those patients. Besides preventing the mobilization and recruitment of endogenous cells, the cell harvest for transplantation is limited by a low frequency of MSCs. Recent work suggested a perivascular origin of MSCs suggesting that multipotent cells are available in virtually all vascularized tissues (Crisan et al., [@B13]). The function of these cells in (local) tissue regeneration has, however, not been explored to date. It has still not been determined to which extent the abundance and regeneration potential of these perivascular MSCs (pericytes) are affected by certain disease states, i.e., the situation of fracture non-union. The investigation of the endogenous regeneration potential of these cells might help to develop new strategies for MSC recruitment to the defect site.

Fracture non-union often occurs in elderly patients. Patient age might have an important influence on the bone regeneration capacities, representing another challenge for both the development of suitable models to test therapeutic strategies and finally the treatment of the patients. Preclinical studies are normally performed in young animals, which are in some cases not even skeletally mature and are not representative for bone healing in elderly patients. The age of patients is also an important consideration with regards to MSC functionality as it has been suggested that proliferation and differentiation abilities are altered in MSCs from donors above 50 years (Mendes et al., [@B89]; Zhou et al., [@B131]; Siegel et al., [@B113]).

Although atrophic non-unions are not always avascular (Reed et al., [@B105]) and EPC mobilization appears not to be affected (Mathieu et al., [@B84]), revascularization is an important event in bone regeneration and endochondral bone formation (Gerber et al., [@B31]; Keramaris et al., [@B55]). The molecular mechanisms and timing of the revascularization process are still poorly understood. Most importantly, little is known about how these processes are altered in non-union patients. For the development of strategies to improve the vascularization in bone defects, it might be of interest to adapt methods, which have been well established for the treatment of ischemic diseases.

Conclusion {#S5}
==========

Cell-bases therapies have shown promising results for the repair of bone tissue; for review, see Ma et al. ([@B78]), Romagnoli and Brandi ([@B106]), and Asatrian et al. ([@B3]). Most of these approaches require, however, time- and cost-extensive *in vitro* expansion procedures and finally regulatory issues have to be considered. This has prompted the development of strategies to stimulate native cells. Homing factors supporting the migration of osteoprogenitor and EPCs toward the fracture site have been administered as microspheres, hydrogels, adsorbed to biomaterials, or delivered as plasmid or viral vector. Here, the combination of a pro-angiogenic stimulus (e.g., VEGF) and an osteoinductive signal, such as BMP-2 has shown most promising results. Besides, mobilization of stem- and progenitor cells from their niche has been shown to facilitate bone healing. Although some of the approaches have shown a promising outcome in preclinical studies, the main challenge remains their translation to the clinical situation. In addition, the lack of a good understanding of the pathological mechanisms, in particularly of fracture non-unions, prevents the development of effective therapies.

Conflict of Interest Statement {#S6}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors wish to thank Dr. Martin Stoddard and Dr. Jennifer Bara for proofreading this manuscript.

[^1]: Edited by: Bruno Peault, University of California Los Angeles, USA

[^2]: Reviewed by: Vasif Nejat Hasirci, Middle East Technical University, Turkey; Mikaël M. Martino, Osaka University, Japan

[^3]: Specialty section: This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology
